<?xml version="1.0" encoding="UTF-8"?>
<p>Quercetin [
 <xref rid="B56-molecules-25-05431" ref-type="bibr">56</xref>], kaempferol [
 <xref rid="B47-molecules-25-05431" ref-type="bibr">47</xref>], and baicalein [
 <xref rid="B82-molecules-25-05431" ref-type="bibr">82</xref>], decrease 
 <italic>H. pylori</italic>-related inflammation, reducing TNF-α, IL-1β, and IL-8. In addition, kaempeferol [
 <xref rid="B47-molecules-25-05431" ref-type="bibr">47</xref>], baicalein [
 <xref rid="B82-molecules-25-05431" ref-type="bibr">82</xref>], and baicalin [
 <xref rid="B82-molecules-25-05431" ref-type="bibr">82</xref>,
 <xref rid="B84-molecules-25-05431" ref-type="bibr">84</xref>], act on different virulence factors, reducing the expression of the CagA and VacA genes. Baicalein [
 <xref rid="B82-molecules-25-05431" ref-type="bibr">82</xref>] also promotes a decrease in the capacity of adhesion and invasion of this microorganism and baicalin [
 <xref rid="B82-molecules-25-05431" ref-type="bibr">82</xref>,
 <xref rid="B84-molecules-25-05431" ref-type="bibr">84</xref>], exerts an inhibitory effect on multidrug-resistant strains, significantly reducing the MICs of the antimicrobials amoxicillin and tetracycline when used in combination. This effect was related to the reduced expression of the hefA gene, which is related to efflux pumps, an important mechanism of drug resistance. Thus, this flavonoid can assist in the treatment of resistant 
 <italic>H. pylori</italic> in a complementary way to existing antimicrobials.
</p>
